UVM highlights VGAIN, biomedical work and workforce role in Senate Appropriations briefing
February 05, 2026 | Appropriations, SENATE, Committees, Legislative , Vermont
This article was created by AI summarizing key points discussed. AI makes mistakes, so for full details and context, please refer to the video of the full meeting. Please report any errors so we can fix them. Report an error »
Marlene Trump used her Senate Appropriations appearance to spotlight University of Vermont research activity and how it ties to workforce and economic development in the state.
Trump said UVM has been named an R1 research university and touted extramural funding that brings research dollars into Vermont, including awards connected to a VGAIN tech hub. She said the university received an award of about $3.4 million and a separate roughly $20 million federal award related to semiconductor work; Trump said one award had been frozen during an administrative pause and was later reopened and that all parts of the application were in final review.
On biomedical research, Trump said UVM is hosting the first rural Biola Labs site and highlighted teams working on vaccines. "This is the same research team that developed the RSV vaccine," she said, and she asserted the vaccine has reduced infant hospitalizations globally by about 80 percent since its introduction. She also described researchers working on a vaccine for tick‑borne illnesses.
Trump linked research to workforce outcomes, saying UVM educates students across bachelor's, master's and doctoral programs and prepares graduates for roles in healthcare, engineering and other sectors. She cited student research and commercialization efforts as pathways that attract faculty and research dollars.
What comes next: Trump asked the committee to "keep your eyes peeled" on the VGAIN project and said grant reviews were in final stages. The presentation framed research and commercialization as both economic development and public‑health investments for Vermont.
Trump said UVM has been named an R1 research university and touted extramural funding that brings research dollars into Vermont, including awards connected to a VGAIN tech hub. She said the university received an award of about $3.4 million and a separate roughly $20 million federal award related to semiconductor work; Trump said one award had been frozen during an administrative pause and was later reopened and that all parts of the application were in final review.
On biomedical research, Trump said UVM is hosting the first rural Biola Labs site and highlighted teams working on vaccines. "This is the same research team that developed the RSV vaccine," she said, and she asserted the vaccine has reduced infant hospitalizations globally by about 80 percent since its introduction. She also described researchers working on a vaccine for tick‑borne illnesses.
Trump linked research to workforce outcomes, saying UVM educates students across bachelor's, master's and doctoral programs and prepares graduates for roles in healthcare, engineering and other sectors. She cited student research and commercialization efforts as pathways that attract faculty and research dollars.
What comes next: Trump asked the committee to "keep your eyes peeled" on the VGAIN project and said grant reviews were in final stages. The presentation framed research and commercialization as both economic development and public‑health investments for Vermont.
Don't Miss a Word: See the Full Meeting!
Go beyond summaries. Unlock every video, transcript, and key insight with a Founder Membership.
✓
Get instant access to full meeting videos
✓
Search and clip any phrase from complete transcripts
✓
Receive AI-powered summaries & custom alerts
✓
Enjoy lifetime, unrestricted access to government data
30-day money-back guarantee
